First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial gives participants a combination of ruxolitinib and systemic corticosteroids as first-line therapy for grade II acute graft-versus-host disease occurring within 100 days after an allogeneic stem cell transplant. Eligible participants are those with hematologic disease who had a first allo-HSCT and present with new onset grade II or intermediate/high-risk aGVHD by modified Glucksberg criteria. The study will monitor clinical response rates and safety outcomes—including infections and organ function—while following participants through the acute treatment period. The goal is to determine whether the combination improves initial response and prevents progression compared with historical steroid-alone outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosed with hematological diseases.
2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.
3. New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.

Exclusion Criteria:

1. Recipients of second allogeneic stem cell transplant.
2. Acute GVHD induced by donor lymphocyte infusion, interferon.
3. Received first line aGVHD treatment before enrollment.
4. Overlap GVHD syndrome.
5. Pregnant or breast-feeding women.
6. Pregnant or breast-feeding women.
7. Serum creatinine \> 2.0 mg/dL or creatinine clearance \< 40 mL/min measured or calculated by Cockroft-Gault equation.
8. Uncontrolled infection.
9. Human immunodeficiency virus infection.
10. Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.
11. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.
12. Allergic history to Janus kinase inhibitors.
13. Severe organ dysfunction unrelated to underlying GVHD, including:

(1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).

(2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.

(3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.

14.Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Where it's running

• Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Liping Dou, M.D., Ph.D.
• Email: lipingruirui@163.com
• Phone: 010-66937079

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining ruxolitinib with corticosteroids for severe acute graft‑versus‑host disease

  This trial tests whether adding ruxolitinib to corticosteroids as first‑line treatment helps people who develop severe acute graft‑versus‑host disease after a first stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07509749

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• Individualized ATG dosing for stem cell transplantation

  This study is testing a personalized approach to dosing a medication for adults receiving stem cell transplants to see if it can reduce complications like infections and improve recovery.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06572462

• Digital application to improve sexual health for stem cell transplant survivors

  This study is testing a new app to help survivors of stem cell transplants improve their sexual health and overall well-being.

  Recruiting Massachusetts General Hospital · Coral Gables, Florida and 2 other locations · NCT06541002

• Modified second transplantation for patients with graft failure

  This study is testing a new approach to a second stem cell transplant for patients who didn't fully recover after their first transplant to see if it helps them get better, especially with their platelet counts.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06512545

• Second haploidentical stem cell transplantation for graft failure

  This study is testing if a second stem cell transplant from a partially matched donor can help patients with blood cancers who had problems with their first transplant.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06512519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.